Approved SEP 28 2007

1 1.14.1.3 Draft Labeling Text

2	Rituxan	®
---	---------	---

3	(Rituximab)
4	WARNINGS
5	Fatal Infusion Reactions: Deaths within 24 hours of Rituxan infusion
6	have been reported. These fatal reactions followed an infusion reaction
7	complex, which included hypoxia, pulmonary infiltrates, acute respiratory
8	distress syndrome, myocardial infarction, ventricular fibrillation, or
9	cardiogenic shock. Approximately 80% of fatal infusion reactions
10	occurred in association with the first infusion. (See WARNINGS and
11	ADVERSE REACTIONS.)
12 13	Patients who develop severe infusion reactions should have Rituxan infusion discontinued and receive medical treatment.
14	Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis
15	with instances of fatal outcome has been reported in the setting of TLS
16	following treatment of non-Hodgkin's lymphoma (NHL) patients with
17	Rituxan. (See WARNINGS.)
18	Severe Mucocutaneous Reactions: Severe mucocutaneous reactions,
19	some with fatal outcome, have been reported in association with Rituxan
20	treatment. (See WARNINGS and ADVERSE REACTIONS.)
21	Progressive Multifocal Leukoencephalopathy (PML): JC virus
22	infection resulting in PML and death has been reported in patients treated
23	with Rituxan. (See WARNINGS and ADVERSE REACTIONS.)
24	DESCRIPTION
24	The Rituxan [®] (Rituximab) antibody is a genetically engineered chimeric
23 26	murine/human monoclonal antibody directed against the CD20 antigen
20 27	found on the surface of normal and malignant B lymphocytes. The
	TOWIG ON MO DULLADO OF HOLIMA AND HUMBHAND P 17 HIPHOD/001 THO

- antibody is an IgG₁ kappa immunoglobulin containing murine light- and
- 29 heavy-chain variable region sequences and human constant region

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 1 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 30 sequences. Rituximab is composed of two heavy chains of 451 amino
- acids and two light chains of 213 amino acids (based on cDNA analysis)
- 32 and has an approximate molecular weight of 145 kD. Rituximab has a
- 33 binding affinity for the CD20 antigen of approximately 8.0 nM.

The chimeric anti-CD20 antibody is produced by mammalian cell
(Chinese Hamster Ovary) suspension culture in a nutrient medium

36 containing the antibiotic gentamicin. Gentamicin is not detectable in the

37 final product. The anti-CD20 antibody is purified by affinity and ion

38 exchange chromatography. The purification process includes specific

39 viral inactivation and removal procedures. Rituximab Drug Product is

40 manufactured from bulk Drug Substance manufactured by Genentech, Inc.

41 (US License No. 1048).

42 Rituxan is a sterile, clear, colorless, preservative-free liquid concentrate

43 for intravenous (IV) administration. Rituxan is supplied at a concentration

44 of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use

45 vials. The product is formulated for IV administration in 9 mg/mL sodium

46 chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mL

47 polysorbate 80, and Water for Injection. The pH is adjusted to 6.5.

48 CLINICAL PHARMACOLOGY

49 General

50 Rituximab binds specifically to the antigen CD20 (human

51 B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic 52 transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes.^{1,2} The antigen is also 53 54 expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL),³ but is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or 55 other normal tissues.⁴ CD20 regulates an early step(s) in the activation 56 process for cell cycle initiation and differentiation,⁴ and possibly functions 57 58 as a calcium ion channel.⁵ CD20 is not shed from the cell surface and does not internalize upon antibody binding.⁶ Free CD20 antigen is not 59 found in the circulation.² 60

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 2 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 61 B-cells are believed to play a role in the pathogenesis of rheumatoid
- 62 arthritis (RA) and associated chronic synovitis. In this setting, B-cells
- 63 may be acting at multiple sites in the autoimmune/inflammatory process,
- 64 including through production of rheumatoid factor (RF) and other
- 65 autoantibodies, antigen presentation, T cell activation, and/or
- 66 pro-inflammatory cytokine production.⁷

67 Preclinical Pharmacology and Toxicology

- 68 Mechanism of Action: The Fab domain of Rituximab binds to the
- 69 CD20 antigen on B lymphocytes, and the Fc domain recruits immune
- 70 effector functions to mediate B-cell lysis in vitro. Possible mechanisms of
- 71 cell lysis include complement-dependent cytotoxicity (CDC)⁸ and
- 72 antibody-dependent cell mediated cytotoxicity (ADCC). The antibody has
- been shown to induce apoptosis in the DHL-4 human B-cell lymphoma
- 74 line.⁹
- 75 Normal Tissue Cross-reactivity: Rituximab binding was observed on
- 76 lymphoid cells in the thymus, the white pulp of the spleen, and a majority
- of B lymphocytes in peripheral blood and lymph nodes. Little or no
- 78 binding was observed in the non-lymphoid tissues examined.

79 **Pharmacokinetics**

- 80 In patients with NHL given single doses at 10, 50, 100, 250 or 500 mg/m^2
- 81 as an IV infusion, serum levels and the half-life of Rituximab were
- 82 proportional to dose.¹⁰ In 14 patients given 375 mg/m^2 as an IV infusion
- for 4 weekly doses, the mean serum half-life was 76.3 hours (range,
- 31.5 to 152.6 hours) after the first infusion and 205.8 hours (range, 83.9 to
- 85 407.0 hours); after the fourth infusion.^{11, 12, 13} The wide range of half-lives
- 86 may reflect the variable tumor burden among patients and the changes in
- 87 CD20-positive (normal and malignant) B-cell populations upon repeated
- 88 administrations.
- 89 Rituxan at a dose of 375 mg/m^2 was administered as an IV infusion at
- 90 weekly intervals for 4 doses to 203 patients with NHL naive to
- 91 Rituxan.^{13, 14} The mean C_{max} following the fourth infusion was

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 3 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

92 486 mcg/mL (range, 77.5–996.6 mcg/mL). The peak and trough serum 93 levels of Rituximab were inversely correlated with baseline values for the 94 number of circulating CD20-positive B-cells and measures of disease burden. Median steady-state serum levels were higher for responders 95 compared with nonresponders; however, no difference was found in the 96 97 rate of elimination as measured by serum half-life. Serum levels were higher in patients with International Working Formulation (IWF) subtypes 98 B, C, and D as compared with those with subtype A.^{11,14} Rituximab was 99 100 detectable in the serum of patients 3 to 6 months after completion of 101 treatment. Rituxan at a dose of 375 mg/m^2 was administered as an IV infusion at 102

102 Retuxan at a dose of 373 mg/m was administered as an 1° midsion at 103 weekly intervals for 8 doses to 37 patients with NHL.¹⁵ The mean C_{max} 104 after 8 infusions was 550 mcg/mL (range, 171-1177 mcg/mL). The mean 105 C_{max} increased with each successive infusion through the eighth infusion 106 (Table 1).

> Mean C_{max} Infusion Range Number mcg/mL mcg/mL 1 242.6 16.1-581.9 2 106.8-948.6 357.5 110.5-731.2 3 381.3 138.0-835.8 460.0 4 5 475.3 156.0-929.1 152.7-865.2 515.4 6 7 187.0-936.8 544.6 170.6-1177.0 550.0 8

Table 1Rituximab Cmax Values

107

108 The pharmacokinetic profile of Rituxan when administered as 6 infusions

109 of 375 mg/m² in combination with 6 cycles of CHOP chemotherapy was

110 similar to that seen with Rituxan alone.¹⁶

- 111 Following the administration of 2 doses of Rituximab in patients with
- 112 rheumatoid arthritis, the mean C_{max} values were 183 mcg/mL (CV=24%)

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 4 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- for the 2×500 mg dose and 370 mcg/mL (CV=25%) for the 2×1000 mg
- 114 dose, respectively. Following 2×1000 mg Rituximab dose, mean volume
- 115 of distribution at steady state was 4.3 L (CV=28%). Mean systemic
- serum clearance of Rituximab was 0.01 L/h (CV=38%), and mean
- 117 terminal elimination half-life after the second dose was 19 days
- 118 (CV=32%).

119 **Special Populations**

120 Gender: The female patients with RA (n=86) had a 37% lower clearance 121 of Rituximab than male patients with RA (n=25). The gender difference 122 in Rituximab clearance does not necessitate any dose adjustment because 123 safety and efficacy of Rituximab do not appear to be influenced by gender.

The pharmacokinetics of Rituximab have not been studied in children and
adolescents. No formal studies were conducted to examine the effects of
either renal or hepatic impairment on the pharmacokinetics of Rituximab.

127 **Pharmacodynamics**

128 Administration of Rituxan resulted in a rapid and sustained depletion of 129 circulating and tissue-based B-cells. Lymph node biopsies performed 130 14 days after therapy showed a decrease in the percentage of B-cells in 131 seven of eight patients with NHL who had received single doses of Rituximab $\geq 100 \text{ mg/m}^{2.10}$ Among the 166 patients in the pivotal NHL 132 133 study, circulating B-cells (measured as CD19-positive cells) were depleted 134 within the first three doses with sustained depletion for up to 6 to 9 months post-treatment in 83% of patients.¹⁴ Of the responding patients assessed 135 136 (n=80), 1% failed to show significant depletion of CD19-positive cells 137 after the third infusion of Rituximab as compared to 19% of the 138 nonresponding patients. B-cell recovery began at approximately 6 months 139 following completion of treatment. Median B-cell levels returned to normal by 12 months following completion of treatment.¹⁴ 140

141 There were sustained and statistically significant reductions in both IgM142 and IgG serum levels observed from 5 through 11 months following

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 5 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

143 Rituximab administration. However, only 14% of patients had reductions
144 in IgM and/or IgG serum levels, resulting in values below the normal
145 range.¹⁴

In RA patients, treatment with Rituxan induced depletion of peripheral
B lymphocytes, with all patients demonstrating near complete depletion
within 2 weeks after receiving the first dose of Rituxan. The majority of
patients showed peripheral B-cell depletion for at least 6 months, followed
by subsequent gradual recovery after that timepoint. A small proportion
of patients (4%) had prolonged peripheral B-cell depletion lasting more

152 than 3 years after a single course of treatment.

153 In RA studies, total serum immunoglobulin levels, IgM, IgG, and IgA

154 were reduced at 6 months with the greatest change observed in IgM.

155 However, mean immunoglobulin levels remained within normal levels

156 over the 24-week period. Small proportions of patients experienced

decreases in IgM (7%), IgG (2%), and IgA (1%) levels below the lower

158 limit of normal. The clinical consequences of decreases in

159 immunoglobulin levels in RA patients treated with Rituxan are unclear.

160 Treatment with Rituximab in patients with RA was associated with

161 reduction of certain biologic markers of inflammation such as

162 interleukin-6 (IL-6), C-reactive protein (CRP), serum amyloid protein

163 (SAA), S100 A8/S100 A9 heterodimer complex (S100 A8/9),

164 anti-citrullinated peptide (anti-CCP) and RF.

165 CLINICAL STUDIES

166 Relapsed or Refractory, Low-Grade or Follicular, CD-20
 167 Positive, B-Cell NHL

168 Rituxan regimens tested include treatment weekly for 4 doses and

169 treatment weekly for 8 doses. Results for studies with a collective

170 enrollment of 296 patients are summarized below (Table 2):

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 6 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

Table 2

Summary of Rituxan Efficacy Data by Schedule and Clinical Setting (See ADVERSE REACTIONS for

· · ·	Study 1 Weekly×4 N=166	Study 2 Weekly×8 N=37	Study 1 and Study 3 Bulky disease, Weekly \times 4 N=39 ^a	Study 3 Retreatment, Weekly×4 N=60
Overall Response Rate	48%	57%	36%	38%
Complete Response Rate	6%	14%	3%	10%
Median Duration of Response ^{b, c, d} (Months) [Range]	11.2 [1.9 to 42.1+]	13.4 [2.5 to 36.5+]	6.9 [2.8 to 25.0+]	15.0 [3.0 to 25.1+]

Risk Factors Associated with Increased Rates of Adverse Events)

^a Six of these patients are included in the first column. Thus, data from 296 intent to treat patients are provided in this table.

^b Kaplan-Meier projected with observed range.

^c "+" indicates an ongoing response.

^d Duration of response: interval from the onset of response to disease progression.

171

172 Weekly for 4 Doses

173 Study 1

174 A multicenter, open-label, single-arm study was conducted in 166 patients

175 with relapsed or refractory, low-grade or follicular B-cell NHL who

176 received 375 mg/m^2 of Rituxan given as an IV infusion weekly for

177 4 doses.¹⁴ Patients with tumor masses > 10 cm or with

178 > 5000 lymphocytes/microliter in the peripheral blood were excluded from

the study. Results are summarized in Table 2. The median time to onset

180 of response was 50 days and the median duration of response was

181 11.2 months (range, 1.9–42.1+). Disease-related signs and symptoms

182 (including B-symptoms) were present in 23% (39/166) of patients at study

183 entry and resolved in 64% (25/39) of those patients.

184 In a multivariate analysis, the ORR was higher in patients with IWF B, C,

and D histologic subtypes as compared to IWF subtype A (58% vs. 12%),

186 higher in patients whose largest lesion was <5 cm vs. >7 cm (maximum,

- 187 21 cm) in greatest diameter (53% vs. 38%), and higher in patients with
- 188 chemosensitive relapse as compared with chemoresistant (defined as

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 7 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 189 duration of response <3 months) relapse (53% vs. 36%). ORR in patients
- 190 previously treated with autologous bone marrow transplant was 78%
- 191 (18/23). The following adverse prognostic factors were not associated
- 192 with a lower response rate: age ≥ 60 years, extranodal disease, prior
- 193 anthracycline therapy, and bone marrow involvement.
- 194 Weekly for 8 Doses
- 195 Study 2
- 196 In a multicenter, single-arm study, 37 patients with relapsed or refractory,
- 197 low-grade NHL received 375 mg/m² of Rituxan weekly for 8 doses.
- 198 Results are summarized in Table 2. (See ADVERSE REACTIONS:
- 199 Risk Factors Associated with Increased Rates of Adverse Events.)
- 200 Bulky Disease, Weekly for 4 Doses
- 201 In pooled data (Study 1 and 3) from multiple studies of Rituxan,
- 202 39 patients with relapsed or refractory, bulky disease (single lesion
- 203 > 10 cm in diameter), low-grade NHL received 375 mg/m² of Rituxan
- 204 weekly for 4 doses. Results are summarized in Table 2.^{16, 17} (For
- 205 information on the higher incidence of Grade 3 and 4 adverse events, see
- 206 ADVERSE REACTIONS: Risk Factors Associated with Increased
- 207 Rates of Adverse Events.)
- 208 Retreatment Weekly for 4 Doses
- 209 Study 3
- 210 In a multicenter, single-arm study, 60 patients received 375 mg/m^2 of
- 211 Rituxan weekly for 4 doses.¹⁸ All patients had relapsed or refractory,
- 212 low-grade or follicular B-cell NHL and had achieved an objective clinical
- 213 response to Rituxan administered 3.8–35.6 months (median 14.5 months)
- 214 prior to retreatment with Rituxan. Of these 60 patients, 55 received their
- 215 second course of Rituxan, 3 patients received their third course and
- 216 2 patients received their second and third courses of Rituxan in this study.
- 217 Results are summarized in Table 2.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 8 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc 218 Previously Untreated, Follicular, CD-20 Positive, B-Cell NHL

219 Study 4

- 220 A total of 322 patients with previously untreated follicular NHL were
- randomized (1:1) to receive up to eight 3-week cycles of CVP
- 222 chemotherapy alone (CVP) or in combination with Rituxan 375 mg/m² on
- 223 Day 1 of each cycle (R-CVP) in an open-label, multicenter study. The
- 224 main outcome measure of the study was progression-free survival (PFS)
- 225 defined as the time from randomization to the first of progression, relapse
- or death.
- 227 Twenty-six percent of the study population was >60 years of age, 99%
- had Stage III or IV disease, and 50% had an International Prognostic
- Index (IPI) score ≥ 2 . Of the 289 patients with available histologic
- 230 material for review, 95% had a centrally-confirmed diagnosis of follicular
- 231 (REAL follicular grade 1, 2 and 3) NHL. The results for PFS as
- 232 determined by a blinded, independent assessment of progression are
- 233 presented in Table 3. The point estimates may be influenced by the
- 234 presence of informative censoring. The PFS results based on investigator
- assessment of progression were similar to those obtained by the
- 236 independent review assessment.

Table 3Efficacy Results in Study 4

	Study Arm	
	CVP	R-CVP
Median PFS (years) ^a	1.4	2.4
Hazard ratio (95% CI) ^b	0.44 (0.29, 0.65)	

^a p<0.0001, two-sided stratified log-rank test.

^b Estimates of Cox regression stratified by center.

- 237
- 238 Previously Untreated, Low-Grade, CD-20 Positive, B-Cell NHL
- 239 Study 5
- A total of 322 patients with previously untreated low-grade, B-cell NHL
- 241 (IWF Grades A, B or C) who did not progress after 6 or 8 cycles of CVP

- chemotherapy were enrolled in an open-label, multicenter, randomized 242 trial. Patients were randomized (1:1) to receive Rituxan, $375 \text{ mg/m}^2 \text{ IV}$ 243 infusion, once weekly for 4 doses every 6 months for up to 16 doses or no 244 further therapeutic intervention. The main outcome measure of the study 245 was progression-free survival defined as the time from randomization to 246 247 progression, relapse or death. Thirty-seven percent of the study population was >60 years of age, 99% had Stage III or IV disease, and 248 249 63% had an IPI score ≥ 2 . Among the 237 patients for whom histologic 250 material was available for review, 201 patients (85%) had centrally 251 confirmed IWF Grade A, B or C NHL.
- 252 There was a reduction in the risk of progression, relapse, or death (hazard
- 253 ratio estimate in the range of 0.36 to 0.49) for patients randomized to
- 254 Rituxan as compared to those who received no additional treatment.

255 Diffuse Large B-Cell NHL (DLBCL)

- 256 The safety and effectiveness of Rituxan were evaluated in three,
- 257 randomized, active-controlled, open-label, multicenter studies with a
- 258 collective enrollment of 1854 patients. Patients with previously untreated
- 259 diffuse large B-cell NHL received Rituxan in combination with
- 260 cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or
- 261 other anthracycline-based chemotherapy regimens.

262 Study 6

- A total of 632 patients aged \geq 60 years with B-cell NHL Grade F, G, or H
- 264 by the International Working Formulation classification or DLBCL
- 265 (including primary mediastinal B-cell lymphoma) in the REAL
- 266 classification were randomized in a 1:1 ratio to treatment with CHOP or
- 267 R-CHOP. Patients were given 6 or 8, 21 day cycles of CHOP. Patients in
- 268 the R-CHOP arm also received 4 or 5 doses of Rituxan 375 mg/m² on
- 269 Days -7 and -3 (prior to Cycle 1), and 48–72 hours pre-Cycle 3,
- 270 pre-Cycle 5, and pre-Cycle 7 for patients receiving 8 cycles of CHOP
- 271 induction. The main outcome measure of the study was progression-free
- 272 survival, defined as the time from randomization to the first of

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 10 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc progression, relapse or death. Responding patients underwent a secondrandomization to receive Rituxan or no further therapy.

275 Among all enrolled patients, 62% had centrally confirmed DLBCL

histology, 73% had Stage III–IV disease, 56% had IPI scores $\geq 2, 86\%$

had ECOG performance status of <2, 57% had elevated LDH levels, and

278 30% had two or more extranodal disease sites involved. Efficacy results

are presented in Table 4. These results reflect a statistical approach which

allows for an evaluation of Rituxan administered in the induction setting

that excludes any potential impact of Rituxan given after the second

282 randomization.

283 Analysis of results after the second randomization in Study 6 demonstrates

that for patients randomized to R-CHOP, additional Rituxan exposure

285 beyond induction was not associated with further improvements in

286 progression free survival or overall survival.

287 Study 7

288 A total of 399 patients with DLBCL, aged ≥ 60 years, were randomized in 289 a 1:1 ratio to receive CHOP or R-CHOP induction. All patients received 290 up to 8, 3-week cycles of CHOP induction; patients in the R-CHOP arm received Rituxan 375 mg/m^2 on Day 1 of each cycle. The main outcome 291 292 measure of the study was event free survival, defined as the time from 293 randomization to relapse, progression, change in therapy or death from 294 any cause. Among all enrolled patients, 80% had stage III or IV disease, 295 60% of patients had an age-adjusted IPI ≥ 2 , 80% had ECOG performance status scores <2, 66% had elevated LDH levels, and 52% had extranodal 296 297 involvement in at least two sites. Efficacy results are presented in Table 4.

298 Study 8

A total of 823 patients with DLBCL, aged 18–60 years, were randomized
in a 1:1 ratio to receive an anthracycline-containing chemotherapy
regimen alone or in combination with Rituxan. The main outcome
measure of the study was time to treatment failure, defined as time from

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 11 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc 303randomization to the earliest of progressive disease, failure to achieve a304complete response, relapse or death. Among all enrolled patients, 28%305had Stage III–IV disease, 100% had IPI scores of ≤ 1 , 99% had ECOG306performance status of < 2, 29% had elevated LDH levels, 49% had bulky307disease and 34% had extranodal involvement. Efficacy results are308presented in Table 4.

Table 4				
Efficacy Results in Studies 6, 7, and	8			

	Study 6 (n=632)		Study 7 (n=399)		Study 8 (n=823)	
	СНОР	R-CHOP	CHOP	R-CHOP	Chemo	R-Chemo
Main outcome	sur	sion-free vival ears)		ee survival ears)		treatment e (years)
Median of main outcome measure	1.6	3.1	1.1	2.9	NE ^b	NE [₽]
Hazard ratio ^d	0.	.69 ^a	0	.60 ^a	0	.45ª
Overall survival at 2 years ^c	63%	74%	58%	69%	86%	95%
Hazard ratio ^d	0	.72ª	0	.68 ^a	0	.40 ^a

^a Significant at p<0.05, 2-sided.

^b NE = Not reliably estimable.

^c Kaplan-Meier estimates.

^d R-CHOP vs. CHOP.

310 In Study 7, overall survival estimates at 5 years were 58% vs. 46% for

311 R-CHOP and CHOP, respectively.

312 Rheumatoid Arthritis (RA)

313 The efficacy and safety of Rituxan were evaluated in 517 patients with

314 active disease who were receiving methotrexate and had a prior inadequate

- 315 response to at least one TNF inhibitor. Patients were ≥ 18 years,
- 316 diagnosed with RA according to American College of Rheumatology
- 317 (ACR) criteria and had at least 8 swollen and 8 tender joints. Patients
- 318 received 2 doses of either Rituxan 1000 mg or placebo as an IV infusion

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 12 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

³⁰⁹

- on days 1 and 15, in combination with continued methotrexate 10–25 mgweekly.
- 321 Efficacy was assessed at 24 weeks. Glucocorticoids were given IV as
- 322 premedication prior to each Rituxan infusion and orally on a tapering
- 323 schedule from baseline through Day 16.
- 324 The proportions of Rituxan (1000 mg) treated patients achieving ACR 20,
- 325 50, and 70 responses in this study is shown in Table 5.

ACR Responses at Week 24 in Placebo-Controlled Stud (Percent of Patients) (Modified Intent-to-Treat Population				
Response	Placebo+MTX $n=201$	Rituxan+MTX n=298		
ACR 20	18%	51%		
		p<0.0001		
ACR 50	5%	27%		
		p<0.0001		
ACR 70	1%	12%		
		p<0.0001		

Table 5

326

327 Improvement was also noted for all components of ACR response

328 following treatment with Rituxan, as shown in Table 6.

Table 6

Parameter	Placebo (n=2		Rituxan + MTX (n=298)	
(median)	Baseline	Wk 24	Baseline	Wk 24
Tender Joint Count	31.0	27.0	33.0	13.0*
Swollen Joint Count	20.0	19.0	21.0	9.5*
Physician Global Assessment ^a	71.0	69.0	71.0	36.0*
Patient Global Assessment ^a	73.0	68.0	71.0	41.0*
Pain ^a	68.0	68.0	67.0	38.5*
Disability Index (HAQ) ^b	2.0	1.9	1.9	1.5*
CRP (mg/dL)	2.4	2.5	2.6	0.9*

Components of ACR Response (Modified Intent-to-Treat Population)

^a Visual Analogue Scale: 0=best, 100=worst.

^b Disability Index of the Health Assessment Questionnaire: 0=best, 3=worst.


* p<0.001, Rituxan + MTX vs. Placebo + MTX.

329

The time course of ACR 20 response for this study is shown in Figure 1.
Although both treatment groups received a brief course of IV and oral
glucocorticoids, resulting in similar benefits at week 4, higher ACR 20
responses were observed for the Rituxan group by week 8 and were
maintained through week 24 after a single course of treatment
(2 infusions) with Rituxan. Similar patterns were demonstrated for
ACR 50 and 70 responses.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 14 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

Figure 1 ACR 20 Responses Over 24 Weeks



--- Placebo (n=201) --- Rituxan 2x1000mg (n=298)

339

340

341 While the efficacy of Rituxan was supported by two well-controlled trials

342 in RA patients who had inadequate responses to non-biologic DMARDs,

343 but who had not failed TNF antagonist therapy, a favorable risk benefit

344 relationship has not been established in this population (See

345 **PRECAUTIONS.**)

346 INDICATIONS AND USAGE

347 Non-Hodgkin's Lymphoma

348 Rituxan[®] (Rituximab) is indicated for the treatment of patients with

349 relapsed or refractory, low-grade or follicular, CD20-positive, B-cell,

- 350 non-Hodgkin's lymphoma.
- 351 Rituxan[®] (Rituximab) is indicated for the first-line treatment of follicular,
- 352 CD20-positive, B-cell non-Hodgkin's lymphoma in combination with
- 353 CVP chemotherapy.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 15 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

337338

- 354 Rituxan[®] (Rituximab) is indicated for the treatment of low-grade,
- 355 CD20-positive, B-cell non-Hodgkin's lymphoma in patients with stable
- 356 disease or who achieve a partial or complete response following first-line
- 357 treatment with CVP chemotherapy.
- 358 Rituxan[®] (Rituximab) is indicated for the first-line treatment of diffuse
- 359 large B-cell, CD20-positive, non-Hodgkin's lymphoma in combination
- 360 with CHOP or other anthracycline-based chemotherapy regimens.

361 Rheumatoid Arthritis

362 Rituxan[®] (Rituximab) in combination with methotrexate is indicated to

- 363 reduce signs and symptoms in adult patients with moderately- to severely-
- active rheumatoid arthritis who have had an inadequate response to one or
- 365 more TNF antagonist therapies.

366 **CONTRAINDICATIONS**

367 None.

368 WARNINGS (See BOXED WARNINGS)

369 Severe Infusion Reactions (see BOXED WARNINGS and370 ADVERSE REACTIONS)

Rituxan has caused severe infusion reactions. In some cases, these
reactions were fatal. These severe reactions typically occurred during the
first infusion with time to onset of 30–120 minutes. Signs and symptoms

374 of severe infusion reactions may include urticaria, hypotension,

- angioedema, hypoxia, or bronchospasm, and may require interruption of
- 376 Rituxan administration. The most severe manifestations and sequelae
- 377 include pulmonary infiltrates, acute respiratory distress syndrome,
- 378 myocardial infarction, ventricular fibrillation, cardiogenic shock, and
- anaphylactic and anaphylactoid events. In the reported cases, the
- 380 following factors were more frequently associated with fatal outcomes:
- 381 female gender, pulmonary infiltrates, and chronic lymphocytic leukemia
- 382 or mantle cell lymphoma.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 16 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc 383 Management of severe infusion reactions: The Rituxan infusion should be 384 interrupted for severe reactions. Medications and supportive care 385 measures including, but not limited to, epinephrine, antihistamines, 386 glucocorticoids, intravenous fluids, vasopressors, oxygen, bronchodilators, 387 and acetaminophen, should be available for immediate use and instituted 388 as medically indicated for use in the event of a reaction during 389 administration. In most cases, the infusion can be resumed at a 50% 390 reduction in rate (e.g., from 100 mg/hr to 50 mg/hr) when symptoms have 391 completely resolved. Patients requiring close monitoring during first and 392 all subsequent infusions include those with pre-existing cardiac and 393 pulmonary conditions, those with prior clinically significant 394 cardiopulmonary adverse events and those with high numbers of circulating malignant cells ($\geq 25,000/\text{mm}^3$) with or without evidence of 395 high tumor burden. (See WARNINGS: Cardiovascular and 396 397 **ADVERSE REACTIONS.)**

Tumor Lysis Syndrome [TLS] (See BOXED WARNINGS and ADVERSE REACTIONS)

400 Rapid reduction in tumor volume followed by acute renal failure. 401 hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia, have 402 been reported within 12-24 hours after the first Rituxan infusion. Rare 403 instances of fatal outcome have been reported in the setting of TLS 404 following treatment with Rituxan in patients with NHL. The risks of TLS 405 appear to be greater in patients with high numbers of circulating malignant cells ($\geq 25,000/\text{mm}^3$) or high tumor burden. Prophylaxis for TLS should 406 be considered for patients at high risk. Correction of electrolyte 407 408 abnormalities, monitoring of renal function and fluid balance, and 409 administration of supportive care, including dialysis, should be initiated as 410 indicated. Following complete resolution of the complications of TLS, 411 Rituxan has been tolerated when re-administered in conjunction with 412 prophylactic therapy for TLS in a limited number of cases.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 17 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

413 Hepatitis B Reactivation with Related Fulminant Hepatitis

414 Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic

415 failure, and death has been reported in patients with hematologic

416 malignancies treated with Rituxan. The majority of patients received

417 Rituxan in combination with chemotherapy. The median time to the

418 diagnosis of hepatitis was approximately 4 months after the initiation of

419 Rituxan and approximately one month after the last dose.

420 Persons at high risk of HBV infection should be screened before initiation

421 of Rituxan. Carriers of hepatitis B should be closely monitored for

422 clinical and laboratory signs of active HBV infection and for signs of

423 hepatitis during and for up to several months following Rituxan therapy.

424 In patients who develop viral hepatitis, Rituxan and any concomitant

425 chemotherapy should be discontinued and appropriate treatment including

426 antiviral therapy initiated. There are insufficient data regarding the safety

427 of resuming Rituxan therapy in patients who develop hepatitis subsequent

428 to HBV reactivation.

429 Progressive Multifocal Leukoencephalopathy (PML) (See 430 BOXED WARNINGS and ADVERSE REACTIONS)

431 JC virus infection resulting in PML and death has been reported in

432 Rituxan-treated patients with hematologic malignancies or with

433 autoimmune diseases for which Rituxan has not been approved. The

434 majority of patients with hematologic malignancies diagnosed with PML

435 received Rituxan in combination with chemotherapy or as part of a

436 hematopoietic stem cell transplant. The patients with autoimmune

437 diseases had a history of prior, and may also have had concurrent,

438 immunosuppressive therapy and were diagnosed with PML within 12

439 months of their last infusion of Rituxan.

Physicians treating patients with Rituxan should consider PML in any
patient presenting with new onset neurologic manifestations. Consultation
with a neurologist, brain MRI, and lumbar puncture should be considered
as clinically indicated. In patients who develop PML, Rituxan should be

- 444 discontinued and reductions or discontinuation of any concomitant
- 445 chemotherapy or immunosuppressive therapy should be considered.

446 **Other Viral Infections**

- 447 The following additional serious viral infections, either new, reactivated or
- 448 exacerbated, have been identified in clinical studies or postmarketing
- 449 reports. The majority of patients received Rituxan in combination with
- 450 chemotherapy or as part of a hematopoietic stem cell transplant. These
- 451 viral infections included cytomegalovirus, herpes simplex virus,
- 452 parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis C.
- 453 In some cases, the viral infections occurred up to one year following
- 454 discontinuation of Rituxan and have resulted in death.

455 Cardiovascular

- 456 Infusions should be discontinued in the event of serious or life-threatening
- 457 cardiac arrhythmias. Patients who develop clinically significant
- 458 arrhythmias should undergo cardiac monitoring during and after
- 459 subsequent infusions of Rituxan. Patients with pre-existing cardiac
- 460 conditions including arrhythmias and angina have had recurrences of these
- 461 events during Rituxan therapy and should be monitored throughout the
- 462 infusion and immediate post-infusion period.

463 Renal (See BOXED WARNINGS:

464 Tumor Lysis Syndrome [TLS] and ADVERSE REACTIONS)

- 465 Rituxan administration has been associated with severe renal toxicity
- 466 including acute renal failure requiring dialysis and in some cases, has led
- 467 to a fatal outcome in hematologic malignancy patients. Renal toxicity has
- 468 occurred in patients with high numbers of circulating malignant cells
- 469 $(>25,000/\text{mm}^3)$ or high tumor burden who experience tumor lysis
- 470 syndrome and in patients with NHL administered concomitant cisplatin
- 471 therapy during clinical trials. The combination of cisplatin and Rituxan is
- 472 not an approved treatment regimen. If this combination is used in clinical
- 473 trials *extreme caution* should be exercised; patients should be monitored

474 closely for signs of renal failure. Discontinuation of Rituxan should be475 considered for those with rising serum creatinine or oliguria.

476 Severe Mucocutaneous Reactions (See BOXED WARNINGS)

- 477 Mucocutaneous reactions, some with fatal outcome, have been reported in
- 478 patients treated with Rituxan. These reports include paraneoplastic
- 479 pemphigus (an uncommon disorder which is a manifestation of the
- 480 patient's underlying malignancy),¹⁹ Stevens-Johnson syndrome, lichenoid
- 481 dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis.
- 482 The onset of the reaction in the reported cases has varied from 1-13 weeks
- 483 following Rituxan exposure. Patients experiencing a severe
- 484 mucocutaneous reaction should not receive any further infusions and seek
- 485 prompt medical evaluation. Skin biopsy may help to distinguish among
- 486 different mucocutaneous reactions and guide subsequent treatment.
- 487 The safety of readministration of Rituxan to patients with any of these
- 488 mucocutaneous reactions has not been determined.

489 Concomitant use with biologic agents and DMARDs other than

- 490 methotrexate in RA: Limited data are available on the safety of the use
- 491 of biologic agents or DMARDs other than methotrexate in patients
- 492 exhibiting peripheral B cell depletion following treatment with Rituximab.
- 493 Patients should be closely observed for signs of infection if biologic
- 494 agents and/or DMARDs are used concomitantly.

495 **Bowel Obstruction and Perforation**

Abdominal pain, bowel obstruction and perforation, in some cases leading to death, were observed in patients receiving Rituxan in combination with chemotherapy for DLBCL. In post-marketing reports, which include both patients with low-grade or follicular NHL and DLBCL, the mean time to onset of symptoms was 6 days (range 1–77) in patients with documented gastro-intestinal perforation. Complaints of abdominal pain, especially early in the course of treatment, should prompt a thorough diagnostic

503 evaluation and appropriate treatment.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 20 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

504 **PRECAUTIONS**

505 Information for Patients

506 Patients should be provided the Rituxan Patient Information leaflet and

507 provided an opportunity to read it prior to each treatment session.

508 Because caution should be exercised in administering Rituxan to patients

509 with active infections, it is important that the patient's overall health be

510 assessed at each visit and any questions resulting from the patient's

511 reading of the Patient Information be discussed.

512 Laboratory Monitoring

513 Because Rituxan targets all CD20-positive B lymphocytes (malignant and

- 514 nonmalignant), complete blood counts (CBC) and platelet counts should
- 515 be obtained at regular intervals during Rituxan therapy and more
- 516 frequently in patients who develop cytopenias (see
- 517 ADVERSE REACTIONS). The duration of cytopenias caused by
- 518 Rituxan can extend well beyond the treatment period.

519 Drug/Laboratory Interactions

520 There have been no formal drug interaction studies performed with

521 Rituxan. However, renal toxicity was seen with this drug in combination

522 with cisplatin in clinical trials. (See WARNINGS: Renal.) In clinical

523 trials of patients with RA, concomitant administration of methotrexate or

524 cyclophosphamide did not alter the pharmacokinetics of Rituximab.

525 Immunization

526 The safety of immunization with live viral vaccines following Rituxan

527 therapy has not been studied and vaccination with live virus vaccines is

528 not recommended. The ability to generate a primary or anamnestic

- 529 humoral response to vaccination is currently being studied.
- 530 Physicians should review the vaccination status of patients with RA being
- 531 considered for Rituxan treatment and follow the Centers for Disease
- 532 Control and Prevention (CDC) guidelines for adult vaccination with
- 533 non-live vaccines intended to prevent infectious disease, prior to therapy.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 21 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

For patients with NHL, the benefits of primary and/or booster vaccinations
should be weighted against the risks of delay in initiation of Rituxan
therapy.

Use in patients with RA who had no prior inadequate response to 537 TNF antagonists: While efficacy of Rituxan was supported in two 538 539 well-controlled trials in patients with RA with prior inadequate responses 540 to non-biologic DMARDs, a favorable risk benefit relationship has not 541 been established in this population. The use of Rituxan in patients with 542 RA who have no prior inadequate response to one or more TNF antagonists is not recommended (see CLINICAL STUDIES: 543 544 **Rheumatoid Arthritis).**

545 Retreatment in patients with RA: Safety and efficacy of retreatment 546 have not been established in controlled trials. A limited number of 547 patients have received two to five courses (two infusions per course) of 548 treatment in an uncontrolled setting. In clinical trials in patients with RA, 549 most of the patients who received additional courses did so 24 weeks after 550 the previous course and none were retreated sooner than 16 weeks.

551 Carcinogenesis, Mutagenesis, and Impairment of Fertility

552 No long-term animal studies have been performed to establish the

- 553 carcinogenic potential of Rituxan. Studies also have not been completed
- 554 to assess mutagenic potential of Rituxan, or to determine potential effects
- 555 on fertility in males or females. Individuals of childbearing potential
- should use effective contraceptive methods during treatment and for up to
- 557 12 months following Rituxan therapy.

558 **Pregnancy Category C**

- 559 An embryo-fetal developmental toxicity study was performed on pregnant
- 560 cynomolgus monkeys. Animals were administered Rituximab via the
- 561 intravenous route during early gestation (organogenesis period;
- 562 post-coitum days 20 through 50). Rituximab was administered as loading
- doses on post-coitum days 20, 21 and 22, at 15, 37.5 or 75 mg/kg/day, and

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 22 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- then weekly on post-coitum days 29, 36, 43 and 50, at 20, 50 or
- 565 100 mg/kg/week. The 100 mg/kg/week dose resulted in exposures of
- 566 0.8-fold a human 2 g dose based on AUC. Although Rituximab has been
- shown to cross the monkey placenta, there was no evidence of
- 568 teratogenicity under the conditions of the experiment.
- Nonteratogenic effects: Results from the embryo-fetal developmental
 toxicology study described above showed that Rituximab treatment
 produced a decrease in lymphoid tissue B cells in the offspring of treated
- 572 dams.

573 A subsequent pre- and postnatal developmental toxicity study in 574 cynomolgus monkeys was completed to assess developmental toxicity and the recovery of B-cells and immune function in infants exposed to 575 576 Rituximab in utero. Due to the possibility of anti-drug antibody development with a long dosing period, the animals were divided into 577 3 sets of dosing periods: one set received a loading dose of Rituximab (0, 578 15, or 75 mg/kg) every day for 3 days starting on post-coitum day 20 579 followed by weekly administration of Rituximab (0, 20 or 100 mg/kg) 580 through delivery and post-partum day 28 (~25 weeks); a second set 581 582 received a loading dose of Rituximab (15 or 75 mg/kg) every day for 3 days starting on post-coitum day 76 followed by weekly administration 583 of Rituximab (20 or 100 mg/kg) through post-coitum day 134 (~8 weeks); 584 585 a third set received a loading dose of Rituximab (15 or 75 mg/kg) every 586 day for 3 days starting on post-coitum day 132 followed by weekly 587 administration of Rituximab (20 or 100 mg/kg) through delivery and post-partum day 28 (~8 weeks). The decreased B cells and 588 immunosuppression noted in the offspring of pregnant animals treated 589 590 with either 20 or 100 mg/kg/week Rituximab showed a return to normal **5**91 levels and function within 6 months post-birth. However, there are no adequate and well-controlled studies in pregnant women. Because animal 592 593 reproductive studies are not always predictive of human response, this 594 drug should be used during pregnancy only if the potential benefit justifies 595 the potential risk to the fetus.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 23 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

596 Nursing Mothers

- 597 Rituximab was excreted in the milk of lactating cynomolgus monkeys.
- 598 It is not known whether Rituxan is excreted in human milk. Because
- 599 human IgG is excreted in human milk and the potential for absorption and
- 600 immunosuppression in the infant is unknown, women should be advised to
- 601 discontinue nursing until circulating drug levels are no longer detectable.
- 602 (See CLINICAL PHARMACOLOGY.)

603 **Pediatric Use**

The safety and effectiveness of Rituxan in pediatric patients have not been

605 established.

606 Geriatric Use

- 607 Among patients with DLBCL in three randomized, active-controlled trials,
- 608 927 patients received Rituxan in combination with chemotherapy.
- 609 Of these, 396 (43%) were age 65 or greater and 123 (13%) were age 75 or
- 610 greater. No overall differences in effectiveness were observed between
- 611 these subjects and younger subjects. However, elderly patients were more
- 612 likely to experience cardiac adverse events, mostly supraventricular
- 613 arrhythmias. Serious pulmonary adverse events were also more common
- among the elderly, including pneumonia and pneumonitis.
- 615 Clinical studies of Rituxan in previously untreated, low-grade or follicular,
- 616 CD 20-positive, B-cell NHL and in relapsed or refractory, low-grade or
- 617 follicular lymphoma did not include sufficient numbers of subjects
- 618 aged 65 and over to determine whether they respond differently from
- 619 younger subjects.
- 620 Among the 517 patients in the phase 3 RA study, 16% were 65–75 years
- 621 old and 2% were 75 years old and older. The Rituxan ACR 20 response
- for a rates in the older (age ≥ 65 years) vs. younger (age < 65 years) patients
- 623 were similar (53% vs. 51%, respectively). Adverse reactions, including
- 624 incidence, severity, and type of adverse reaction were similar between
- 625 older and younger patients.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 24 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

626 **ADVERSE REACTIONS**

Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may not
reflect the rates observed in practice. The adverse reaction information
from clinical trials does, however, provide a basis for identifying the
adverse events that appear to be related to drug use and for approximating
rates.

The following serious adverse reactions, some with fatal outcomes, have

635 been reported in patients treated with Rituxan (see **BOXED WARNINGS**

- and WARNINGS): severe or fatal infusion reactions, tumor lysis
- 637 syndrome, severe mucocutaneous reactions, hepatitis B reactivation with
- 638 fulminant hepatitis, progressive multifocal leukoencephalopathy (PML),

639 other viral infections, cardiac arrhythmias, renal toxicity, bowel

640 obstruction and perforation.

641 Adverse Reactions in Patients with Non-Hodgkin's Lymphoma

642 The overall safety database for Rituxan is based on clinical trial data from

- 643 1606 patients with NHL, who received Rituxan either as a single agent or
- 644 in combination with chemotherapy. Additional safety information was
- obtained from post-marketing safety surveillance. The most common
- 646 adverse reactions were infusion reactions (see INFUSION REACTIONS
- 647 below).
- 648 Except as noted, adverse events described below occurred in the setting of
- 649 relapsed or refractory, low-grade or follicular, CD20-positive, B-cell,
- 650 NHL and are based on 356 patients treated in single-arm studies of
- 651 Rituxan administered as a single agent. Most patients received Rituxan
- 375 mg/m^2 weekly for 4 doses.
- 653 Infusion Reactions (See **BOXED WARNINGS** and **WARNINGS**)
- 654 Mild to moderate infusion reactions consisting of fever and chills/rigors
- occurred in the majority of patients during the first Rituxan infusion.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 25 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 656 Other frequent infusion reaction symptoms included nausea, pruritus, 657 angioedema, asthenia, hypotension, headache, bronchospasm, throat 658 irritation, rhinitis, urticaria, rash, vomiting, myalgia, dizziness, and 659 hypertension. These reactions generally occurred within 30 to 660 120 minutes of beginning the first infusion, and resolved with slowing or interruption of the Rituxan infusion and with supportive care 661 662 (diphenhydramine, acetaminophen, IV saline, and vasopressors). 663 The incidence of infusion reactions was highest during the first infusion 664 (77%) and decreased with each subsequent infusion (30% with fourth 665 infusion and 14% with eighth infusion). Injection site pain was reported in less than 5% of patients. 666
- 667 Infectious Events (See WARNINGS: Hepatitis B Reactivation
 668 with Related Fulminant Hepatitis; Progressive Multifocal
 669 Leukoencephalopathy (PML)), Other Viral Infections
- 670 Rituxan induced B-cell depletion in 70% to 80% of patients with NHL and
- 671 was associated with decreased serum immunoglobulins in a minority of
- 672 patients; the lymphopenia lasted a median of 14 days (range, 1–588 days).
- 673 Infectious events occurred in 31% of patients: 19% of patients had
- bacterial infections, 10% had viral infections, 1% had fungal infections,
- and 6% were unknown infections. Incidence is not additive because a
- 676 single patient may have had more than one type of infection. Serious
- 677 infectious events (Grade 3 or 4), including sepsis, occurred in 2% of
- 678 patients.

679 Hematologic Events

- 680 Grade 3 and 4 cytopenias were reported in 48% of patients treated with
- 681 Rituxan; these include: lymphopenia (40%), neutropenia (6%),
- 682 leukopenia (4%), anemia (3%), and thrombocytopenia (2%). The median
- duration of lymphopenia was 14 days (range, 1–588 days) and of
- 684 neutropenia was 13 days (range, 2–116 days). A single occurrence of
- 685 transient aplastic anemia (pure red cell aplasia) and two occurrences of
- 686 hemolytic anemia following Rituxan therapy were reported.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 26 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 687 Pulmonary Events
- 688 135 patients (38%) experienced pulmonary events in clinical trials.
- 689 The most common respiratory system adverse events experienced were
- 690 increased cough, rhinitis, bronchospasm, dyspnea, and sinusitis. In both
- 691 clinical studies and post-marketing surveillance, there have been a limited
- number of reports of bronchiolitis obliterans presenting up to 6 months
- 693 post-Rituxan infusion and a limited number of reports of pneumonitis
- 694 (including interstitial pneumonitis) presenting up to 3 months post-Rituxan
- 695 infusion, some of which resulted in fatal outcomes. The safety of
- 696 resumption or continued administration of Rituxan in patients with
- 697 pneumonitis or bronchiolitis obliterans is unknown.
- 698 Immunogenicity
- The observed incidence of antibody positivity in an assay is highly
- 700 dependent on the sensitivity and specificity of the assay and may be
- 701 influenced by several factors including sample handling, concomitant
- 702 medications, and underlying disease. For these reasons, comparison of the
- 703 incidence of antibodies to Rituxan with the incidence of antibodies to
- other products may be misleading.
- 705 In clinical studies of patients with low-grade or follicular NHL receiving
- 706 single-agent Rituxan, human antichimeric antibody (HACA) was detected
- in 4 of 356 (1.1%) patients and 3 had an objective clinical response.
- 708 These data reflect the percentage of patients whose test results were
- 709 considered positive for antibodies to Rituxan using an enzyme-linked
- 710 immunosorbant assay (limit of detection = 7 ng/mL).

Single Agent Rituxan for Relapsed or Refractory, Low-Grade or Follicular, CD20-Positive, B-Cell NHL

- 713 The data below were obtained in 356 patients receiving single agent
- 714 Rituxan for treatment of relapsed, refractory, low grade or follicular NHL
- 715 (see CLINICAL STUDIES). The majority of patients received
- 716 375 mg/m^2 IV weekly × 4 doses. The median age was 57 (range
- 717 22–81 years). Sixty percent were male; 93% were Caucasian, 1% were

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 27 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 718 Black, 2% were Hispanic, 2% were Asian, and 2% were from other racial
- 719 groups.
- Table 7 lists the most common, as well as Grade 3 and 4, adverse events
- 721 observed.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 28 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

Table 7

Incidence of Adverse Events in \geq 5% of Patients with Relapsed or Refractory, Low-Grade or Follicular NHL, Receiving Single-agent Rituxan (N=356)^{a,b}

	All Grades (%)	Grade 3 and 4 (%)
Any Adverse Events	99	57
Body as a Whole	86	10
Fever	53	1
Chills	33	3
Infection	31	4
Asthenia	26	1
Headache	19	1
Abdominal Pain	14	1
Pain	12	1
Back Pain	10	1
Throat Irritation	9	0
Flushing	5	0
Cardiovascular System	25	3
Hypotension	10	1
Hypertension	6	1
Digestive System	37	2
Nausea	23	1
Diarrhea	10	1
Vomiting	10	1
Hemic and Lymphatic System	67	48
Lymphopenia	48	40
Leukopenia	14	4
Neutropenia	14	6
Thrombocytopenia	12	2
Anemia	8	3
Metabolic and Nutritional Disorders	38	3
Angioedema	11	1
Hyperglycemia	9	1
Peripheral Edema	8	0
LDH Increase	7	0

722

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 29 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

Table 7 (cont'd)

Incidence of Adverse Events in \geq 5% of Patients with Relapsed or Refractory, Low-Grade or Follicular NHL, Receiving Single-agent Rituxan (N=356)^{a,b}

	All Grades (%)	Grade 3 and 4 (%)
Musculoskeletal System	26	3
Myalgia	10 .	1
Arthralgia	10	1
Nervous System	32	1
Dizziness	10	1
Anxiety	5	· 1
Respiratory System	38	4
Increased Cough	13	1
Rhinitis	12	1
Bronchospasm	8	1
Dyspnea	7	1
Sinusitis	6	0
Skin and Appendages	44	. 2
Night Sweats	15	1
Rash	15	. 1
Pruritus	14	1
Urticaria	8	1

^a Adverse Events observed up to 12 months following Rituxan.

^b Adverse Events graded for severity by NCI-CTC criteria²⁰.

723

Risk Factors Associated With Increased Rates of Adverse Events
Administration of Rituxan weekly for 8 doses resulted in higher rates of

726 Grade 3 and 4 adverse events¹⁵ overall (70%) compared with

administration weekly for 4 doses (57%). The incidence of Grade 3 or 4

728 adverse events was similar in patients retreated with Rituxan compared

with initial treatment (58% and 57%, respectively). The incidence of the

730 following clinically significant adverse events was higher in patients with

731 bulky disease (lesions ≥ 10 cm) (N=39) versus patients with lesions

<10 cm (N=195): abdominal pain, anemia, dyspnea, hypotension, and
 neutropenia.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 30 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

734 Previously Untreated, Follicular, CD20-Positive, B-Cell NHL

735 The safety data were obtained in a single, multi-center, randomized study

736 of 321 patients of whom 162 received Rituxan in combination with CVP

chemotherapy (R-CVP) and 159 received CVP chemotherapy alone

738 (CVP). Eighty-five percent of R-CVP patients received the maximum

number of doses (8) of Rituxan. The median age was 52 years, 54% were

740 male, and 96% were Caucasian.

741 Patients in the R-CVP arm had higher incidences of infusional toxicity and

742 of neutropenia as compared to those in the CVP arm. The following

adverse events occurred more frequently (\geq 5%) in patients receiving

744 R-CVP compared to CVP alone: rash (17% vs. 5%), cough

745 (15% vs. 6%), flushing (14% vs. 3%), rigors (10% vs. 2%), pruritus

746 (10% vs. 1%), neutropenia (8% vs. 3%), and chest tightness (7% vs. 1%).

747 Previously Untreated, Low-Grade, CD20-Positive, B-Cell NHL

748 Safety data were obtained in a single, multi-center, randomized study of

749 322 patients of whom 161 received Rituxan and 161 received no treatment

750 following 6–8 cycles of CVP chemotherapy. Ninety-five patients (59%)

751 received the maximum number of doses (16) of Rituxan.

752 The median age for the Rituxan treated patients was 58 years. Fifty-five

753 percent were male, 93% were Caucasian, and 5% Black.

The following adverse events were reported more frequently (\geq 5%) in

755 patients receiving Rituxan following CVP compared with those who

received no further therapy: fatigue (39% vs. 14%), anemia

757 (35% vs. 20%), peripheral sensory neuropathy (30% vs. 18%), infections

758 (19% vs. 9%), pulmonary toxicity (18% vs. 10%), hepato-biliary toxicity

759 (17% vs. 7%), rash and/or pruritus (17% vs. 5%), arthralgia

760 (12% vs. 3%), and weight gain (11% vs. 4%). Neutropenia was the only

Grade 3 or 4 adverse event that occurred more frequently ($\geq 2\%$) in the

762 Rituxan arm compared with those who received no further therapy

763 (4% vs. 1%).

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 31 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

764 **Rituxan in Combination with Chemotherapy for DLBCL**

- Adverse events described in the setting of DLBCL are based on three
- randomized, active-controlled clinical trials in which 927 patients received
- 767 Rituxan in combination with chemotherapy and 802 patients received
- 768 chemotherapy alone. Detailed safety data collection was primarily limited
- to Grade 3 and 4 adverse events and serious adverse events.
- The population varied from 18–92 years of age and 55% were male; racial
- distribution was collected only for Study 6 (see CLINICAL STUDIES
- section) where 90% of patients were Caucasian, 5% were Black, 3% were
- 773 Hispanic and 2% were from other racial groups. Patients received
- 774 4-8 doses of Rituxan at 375 mg/m².
- The following adverse events, regardless of severity, were reported more
- frequently (\geq 5%) in patients age \geq 60 years receiving R-CHOP as
- compared to CHOP alone: pyrexia (56% vs. 46%), lung disorder (31% vs.
- 24%), cardiac disorder (29% vs. 21%), and chills (13% vs. 4%). In one of
- these studies (Study 7), more detailed assessment of cardiac toxicity
- 780 revealed that supraventricular arrhythmias or tachycardia accounted for
- 781 most of the difference in cardiac disorders, with 4.5% vs. 1.0% incidences
- 782 for R-CHOP and CHOP, respectively.
- 783 The following Grade 3 or 4 adverse events were reported more frequently
- among patients in the R-CHOP arm compared with those in the CHOP
- arm: thrombocytopenia (9% vs. 7%) and lung disorder (6% vs. 3%).
- 786 Other severe adverse events reported more commonly among patients
- 787 receiving R-CHOP in one or more studies were viral infection,
- 788 neutropenia and anemia.
- 789 Adverse Reactions in Patients with Rheumatoid Arthritis
- 790 In general, the adverse events observed in patients with RA were similar
- in type to those seen in patients with non-Hodgkin's lymphoma (see
- 792 WARNINGS, PRECAUTIONS and other sections under

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 32 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 793 ADVERSE REACTIONS). Specific safety considerations in this
- indication are discussed below.
- 795 Where specific percentages are noted, these data are based on 938 patients
- treated in Phase 2 and 3 studies of Rituxan (2×1000 mg) or placebo
- administered in combination with methotrexate.

Table 8

Incidence of All Adverse Events* Occurring in ≥2% and at least 1% Greater than Placebo Among Rheumatoid Arthritis Patients in Clinical Studies Up to Week 24 (Pooled)

Preferred Term	Placebo + MTX N=398 n (%)	Rituxan + MTX N=540 n (%)
Abdominal Pain Upper	4 (1)	11 (2)
Anxiety	5 (1)	9 (2)
Arthralgia	14 (4)	31 (6)
Asthenia	1 (<1)	9 (2)
Chills	9 (2)	16 (3)
Dyspepsia	3 (<1)	16 (3)
Hypercholesterolemia	1 (<1)	9 (2)
Hypertension	21 (5)	43 (8)
Migraine	2 (<1)	9 (2)
Nausea	19 (5)	41 (8)
Paresthesia	3 (<1)	12 (2)
Pruritus	5 (1)	26 (5)
Pyrexia	8 (2)	27 (5)
Rhinitis	6 (2)	14 (3)
Throat Irritation	0 (0)	11 (2)
Upper Respiratory Tract Infection	23 (6)	37 (7)
Urticaria	3 (<1)	12 (2)

* Coded using MedDRA.

798

- 799 Infusion Reactions
- 800 In Rituxan RA placebo-controlled studies, 32% of Rituxan-treated patients
- 801 experienced an adverse event during or within 24 hours following their

802 first infusion, compared to 23% of placebo-treated patients receiving their 803 first infusion. The incidence of adverse events during the 24-hour period 804 following the second infusion, Rituxan or placebo, decreased to 11% and 13%, respectively. Acute infusion reactions (manifested by fever, chills, 805 rigors, pruritus, urticaria/rash, angioedema, sneezing, throat irritation, 806 807 cough, and/or bronchospasm, with or without associated hypotension or hypertension) were experienced by 27% of Rituxan-treated patients 808 following their first infusion, compared to 19% of placebo-treated patients 809 810 receiving their first placebo infusion. The incidence of these acute 811 infusion reactions following the second infusion of Rituxan or placebo 812 decreased to 9% and 11%, respectively. Serious acute infusion reactions 813 were experienced by <1% of patients in either treatment group. Acute 814 infusion reactions required dose modification (stopping, slowing or interruption of the infusion) in 10% and 2% of patients receiving 815 Rituximab or placebo, respectively, after the first course. The proportion 816 817 of patients experiencing acute infusion reactions decreased with 818 subsequent courses of Rituxan. The administration of IV glucocorticoids 819 prior to Rituxan infusions reduced the incidence and severity of such 820 reactions, however, there was no clear benefit from the administration of 821 oral glucocorticoids for the prevention of acute infusion reactions. 822 Patients in clinical studies also received antihistamines and acetaminophen 823 prior to Rituxan infusions.

824 Infections

In RA clinical studies, 39% of patients in the Rituxan group experienced 825 826 an infection of any type compared to 34% of patients in the placebo group. The most common infections were nasopharyngitis, upper respiratory tract 827 infections, urinary tract infections, bronchitis, and sinusitis. The only 828 829 infections to show an absolute increase over placebo of at least 1% were 830 upper respiratory tract infections, which affected 7% of Rituxan-treated 831 patients and 6% of placebo-treated patients and rhinitis, which affected 832 3% of Rituxan-treated patients and 2% of placebo-treated patients.

U.S. BL 103705/5262 Amendment: Rituximab---Genentech, Inc. 34 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 833 The incidence of serious infections was 2% in the Rituxan-treated patients
- and 1% in the placebo group. One fatal infection (bronchopneumonia)
- 835 occurred with Rituximab monotherapy during the 24-weeks
- 836 placebo-controlled period in one of the Phase 2 RA studies.
- 837 Cardiac Events
- The incidence of serious cardiovascular events in the double-blind part of the clinical trials was 1.7% and 1.3% in Rituxan and placebo treatment groups, respectively. Three cardiovascular deaths occurred during the double-blind period of the RA studies including all Rituximab regimens (3/769=0.4%) as compared to none in the placebo treatment group (0/389).
- 844 Since patients with RA are at increased risk for cardiovascular events
- subsection compared with the general population, patients with RA should be
- 846 monitored throughout the infusion and Rituxan should be discontinued in
- 847 the event of a serious or life-threatening cardiac event.

848 Immunogenicity

- A total of 54/990 patients (5%) with RA tested positive for HACA.
- 850 Of these, most became positive by week 24. Following the first course,
- however, some became positive at week 16 or after 24 weeks. Some
- 852 patients tested positive after the second course of treatment. Limited data
- are available on the safety or efficacy of Rituxan retreatment in patients
- 854 who develop HACA. One of 10 HACA-positive patients who received
- 855 retreatment with Rituxan experienced a serious acute infusion reaction
- 856 (bronchospasm). The clinical relevance of HACA formation in
- 857 Rituximab-treated patients is unclear.

858 **Post-Marketing Reports**

- 859 The following adverse reactions have been identified during post-approval
- 860 use of Rituxan in hematologic malignancies. Because these reactions are
- 861 reported voluntarily from a population of uncertain size, it is not always
- 862 possible to reliably estimate their frequency or establish a causal

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 35 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 863 relationship to drug exposure. Decisions to include these reactions in
- labeling are typically based on one or more of the following factors:
- 865 (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength
- 866 of causal connection to Rituxan.
- 867 *Hematologic*: prolonged pancytopenia, marrow hypoplasia, and late onset
- 868 neutropenia, hyperviscosity syndrome in Waldenstrom's
- 869 macroglobulinemia.
- 870 Cardiac: fatal cardiac failure.
- 871 Immune/Autoimmune Events: uveitis, optic neuritis, systemic vasculitis,
- 872 pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis and
- 873 vasculitis with rash.
- 874 *Infection*: viral infections, including progressive multifocal
- 875 leukoencephalopathy (PML), increase in fatal infections in HIV-associated
- 876 lymphoma, and a reported increased incidence of Grade 3 and 4 infections
- 877 in patients with previously treated lymphoma without known HIV
- 878 **infection**.
- 879 *Neoplasia*: disease progression of Kaposi's sarcoma.
- 880 *Skin*: severe mucocutaneous reactions.
- 881 *Gastrointestinal*: bowel obstruction and perforation.

882 OVERDOSAGE

- 883 There has been no experience with overdosage in human clinical trials.
- 884 Single doses of up to 500 mg/m^2 have been given in dose-escalation
- 885 clinical trials.¹⁰

886 DOSAGE AND ADMINISTRATION

887 Relapsed or Refractory, Low-Grade or Follicular,

888 CD20-Positive, B-Cell Non-Hodgkin's Lymphoma

889 The recommended dose of Rituxan is 375 mg/m^2 IV infusion once weekly

890 for 4 or 8 doses.

891 **Retreatment Therapy**

- The recommended dose of Rituxan is 375 mg/m² IV infusion once weekly for 4 doses in responding patients who develop progressive disease after previous Rituxan therapy. Currently there are limited data concerning
- 895 more than 2 courses.

896 Previously Untreated, Follicular, CD20-Positive, B-Cell NHL

- 897 The recommended dose of Rituxan is 375 mg/m² IV infusion, given on
- 898 Day 1 of each cycle of CVP chemotherapy, for up to 8 doses.
- 899 Previously Untreated, Low-Grade, CD20-Positive, B-Cell NHL
- 900 The recommended dose of Rituxan in patients who have not progressed
- following 6–8 cycles of CVP chemotherapy is 375 mg/m^2 IV infusion,
- 902 once weekly for 4 doses every 6 months for up to 16 doses.

903 Diffuse Large B-Cell NHL

- 904 The recommended dose of Rituxan is 375 mg/m^2 IV per infusion given on
- 905 Day 1 of each cycle of chemotherapy for up to 8 infusions.

906 Rheumatoid Arthritis

- 907 Rituxan is given as two-1000 mg IV infusions separated by 2 weeks.
- 908 Glucocorticoids administered as methylprednisolone 100 mg IV or its
- 909 equivalent 30 minutes prior to each infusion are recommended to reduce
- 910 the incidence and severity of infusion reactions. Safety and efficacy of
- 911 retreatment have not been established in controlled trials (see
- 912 **PRECAUTIONS:** Retreatment in patients with RA).
- 913 Rituxan is given in combination with methotrexate.

914 Rituxan as a Component of Zevalin[®] (Ibritumomab tiuxetan) 915 Therapeutic Regimen

- 916 As a required component of the Zevalin therapeutic regimen, Rituxan
- 917 250 mg/m² should be infused within 4 hours prior to the administration of
- 918 Indium-111- (In-111-) Zevalin and within 4 hours prior to the
- 919 administration of Yttrium-90- (Y-90-) Zevalin. Administration of Rituxan
- and In-111-Zevalin should precede Rituxan and Y-90-Zevalin by
- 921 7–9 days. Refer to the Zevalin package insert for full prescribing
- 922 information regarding the Zevalin therapeutic regimen.
- 923 Rituxan may be administered in an outpatient setting. DO NOT
- 924 ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. (See
- 925 Administration).

926 Instructions for Administration

- 927 Preparation for Administration
- 928 Use appropriate aseptic technique. Withdraw the necessary amount of
- 929 Rituxan and dilute to a final concentration of 1 to 4 mg/mL into an
- 930 infusion bag containing either 0.9% Sodium Chloride, USP, or
- 931 5% Dextrose in Water, USP. Gently invert the bag to mix the solution.
- 932 Discard any unused portion left in the vial. Parenteral drug products
- should be inspected visually for particulate matter and discoloration prior
- 934 to administration.
- Rituxan solutions for infusion may be stored at 2°C–8°C (36°F–46°F) for
- 936 24 hours. Rituxan solutions for infusion have been shown to be stable for
- 937 an additional 24 hours at room temperature. However, since Rituxan
- 938 solutions do not contain a preservative, diluted solutions should be stored
- 939 refrigerated (2°C-8°C). No incompatibilities between Rituxan and
- 940 polyvinylchloride or polyethylene bags have been observed.

941 Administration: DO NOT ADMINISTER AS AN INTRAVENOUS942 PUSH OR BOLUS

- 943. Infusion reactions may occur (see BOXED WARNINGS, WARNINGS,
- and ADVERSE REACTIONS). Premedication consisting of

- acetaminophen and an antihistamine should be considered before each
- 946 infusion of Rituxan. Premedication may attenuate infusion reactions.
- 947 Since transient hypotension may occur during Rituxan infusion,
- 948 consideration should be given to withholding antihypertensive
- 949 medications 12 hours prior to Rituxan infusion.

950 First Infusion

- 951 The Rituxan solution for infusion should be administered intravenously at
- 952 an initial rate of 50 mg/hr. Rituxan should not be mixed or diluted with
- 953 other drugs. If infusion reactions do not occur, escalate the infusion rate
- in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
- 955 If an infusion reaction develops, the infusion should be temporarily
- slowed or interrupted (see **BOXED WARNINGS** and **WARNINGS**).
- 957 The infusion can continue at one-half the previous rate upon improvement
- 958 of patient symptoms.
- 959 Subsequent Infusions
- 960 If the patient tolerated the first infusion well, subsequent Rituxan infusions
- 961 can be administered at an initial rate of 100 mg/hr, and increased by
- 962 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr
- 963 as tolerated. If the patient did not tolerate the first infusion well, follow
- 964 the guidelines under First Infusion.

965 **Stability and Storage**

- 966 Rituxan vials are stable at 2°C–8°C (36°F–46°F). Do not use beyond
- 967 expiration date stamped on carton. Rituxan vials should be protected from
- 968 direct sunlight. Do not freeze or shake. Refer to the "Preparation for
- 969 Administration" section for information on the stability and storage of
- 970 solutions of Rituxan diluted for infusion.

971 HOW SUPPLIED

- 972 Rituxan[®] (Rituximab) is supplied as 100 mg and 500 mg of sterile,
- 973 preservative-free, single-use vials.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 39 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc 974 Single unit 100 mg carton: Contains one 10 mL vial of Rituxan

- 975 (10 mg/mL).
- 976 NDC 50242-051-21
- 977 Single unit 500 mg carton: Contains one 50 mL vial of Rituxan
- 978 (10 mg/mL).
- 979 NDC 50242-053-06

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 40 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

980 **REFERENCES**

981 982 983	1.	Valentine MA, Meier KE, Rossie S, et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. <i>J Biol Chem</i> 1989;264(19): 11282–7.
984 985 986	2 [.]	Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. <i>EMBO J</i> 1988;7(3):711–7.
987 988 989	3.	Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation. <i>Blood</i> 1984;63(6):1424–33.
990 991 992	4.	Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B-cell activation and differentiation. <i>J Immunol</i> 1985;135(2):973–9.
993 994 995	5.	Tedder TF, Zhou LJ, Bell PD, et al. The CD20 surface molecule of B lymphocytes functions as a calcium channel. <i>J Cell Biochem</i> 1990;14D:195.
996 997 998	6.	Press OW, Applebaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. <i>Blood</i> 1987;69(2):584–91.
999 1000 1001	7.	Dorner, T, Rumester, G. The role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targets. <i>Curr Op Rheum</i> 2003;15:246–52.
1002 1003 1004	8.	Reff ME, Carner C, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. <i>Blood</i> 1994;83(2):435–45.
1005 1006 1007 1008 1009	9.	Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimericanti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. <i>Cancer Biotherapy & Radiopharmaceuticals</i> 1997;12(3):177–86.
1010 1011 1012 1013 1014	10.	Maloney DG, Liles TM, Czerwinski C, Waldichuk J, Rosenberg J, Grillo-López A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. <i>Blood</i> 1994;84(8):2457–66.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 41 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

1015 1016 1017 1018 1019	11.	Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. <i>Annals of Oncology</i> 1998;9:995–1001.
1020 1021 1022 1023	12.	Maloney DG, Grillo-López AJ, Bodkin D, White CA, Liles T-M, Royston I, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. <i>J Clin</i> <i>Oncol</i> 1997;15(10):3266–74.
1024 1025 1026 1027	13.	Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. <i>Blood</i> 1997;90(6):2188–95.
1028 1029 1030 1031 1032	14.	McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. <i>J Clin Oncol</i> 1998;16(8):2825–33.
1033 1034 1035 1036	15.	Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. <i>Annals of Oncology</i> 1999;10:655–61.
1037	16.	Data on file.
1038 1039 1040 1041	17.	Davis TA, White CA, Grillo-López AJ, Velasquez WS, Lin B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky Non-Hodgkin's lymphoma: results of a phase II trial of rituximab. <i>JCO</i> 1999;17:1851–7.
1042 1043 1044 1045 1046	18.	Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-hodgkin's lymphoma: safety and efficacy of re-treatment. <i>J Clin Oncol</i> 2000;18(17):3135–43.
1047 1048 1049 1050	19.	Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, Mutasim D, Ariss-Abdo L, Labib RS. Paraneoplastic Pemphigus, an autoimmune mucocutaneous disease associated with neoplasia. <i>NEJM</i> 1990;323(25):1729–35.

1051	20.	National Institutes of Health (US), National Cancer Institute.
1052		Common Toxicity Criteria. [Bethesda, MD.] : National Institutes of
1053		Health, National Cancer Institute; c1998;73p.

U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 43 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

Jointly Marketed by: Biogen Idec Inc., and Genentech, Inc.

Rituxan[®] (Rituximab)

Manufactured by:

4835502

Genentech, Inc.	Initial US Approval November 26, 1997
1 DNA Way South San Francisco, CA 94080-4990	Revision Date February 21, 2007
2	[©] 2007 Biogen Idec Inc. and Genentech, Inc.

1054		
1055	Patient Information	
1056	Rituxan [®] (ri-tuk'-san)	
1057	(Rituximab)	
1058	Read this patient information leaflet when you have been prescribed	
1059	Rituxan and each time you are scheduled to receive a Rituxan infusion.	
1060	This information does not take the place of talking to your doctor about	
1061	your medical condition or your treatment. Talk with your doctor if you	
1062	have any questions about your treatment with Rituxan.	
1063 1064	What is the most important safety information I should know about Rituxan?	
1065	Rituxan can cause the following serious side effects, some of which	
1066	could be life-threatening:	
1067 1068 1069 1070	• Infusion reactions. Tell your doctor or get medical treatment right away if you get hives, swelling, dizziness, blurred vision, drowsiness, headache, cough, wheezing, or have trouble breathing while receiving or after receiving Rituxan.	
1071 1072 1073 1074	• Tumor Lysis Syndrome (TLS). TLS is caused by the fast breakdown of certain blood cancers. TLS can cause kidney failure and the need for dialysis treatment. Patients receiving Rituxan for non-Hodgkin's lymphoma may get TLS.	
1075 1076 1077	• Severe skin reactions. Tell your doctor or get medical treatment right away if you get painful sores, ulcers, blisters, or peeling skin while receiving or after receiving Rituxan.	

1078 1079	• Progressive Multifocal Leukoencephalopathy (PML) . PML is a rare brain infection that usually causes death or severe disability.
1080 1081	• PML has been reported in patients during or after their treatment with Rituxan.
1082	• There is no known treatment, prevention, or cure for PML.
1083 1084 1085 1086	• Call your doctor right away if you notice any new or worsening medical problems, such as a new or sudden change in thinking, walking, strength, vision, or other problems that have lasted over several days.
1087	Also, see "What are possible side-effects with Rituxan?" for other serious
1088	side effects, some of which could be life-threatening.
1089	What is Rituxan?
1090	Rituxan is a biologic medicine used in adults:
1091 1092	• alone or with other anti-cancer medicines to treat certain types of non-Hodgkin's lymphoma (NHL).
1093 1094 1095 1096	• with another medicine called methotrexate to reduce the signs and symptoms of Rheumatoid Arthritis (RA) after at least one other medicine called a tumor necrosis factor (TNF) inhibitor has been used and did not work well.
1097	Rituxan has not been studied in children.
1098	How does Rituxan work?
1099	Rituxan works by getting rid of certain B-cells in the blood. B-cells are a
1100	type of white blood cell found in the blood. B-cells usually help the body
1101	fight infection. B-cells play an important role in diseases such as NHL

- and RA. Rituxan may also get rid of healthy B-cells and this can give you 1102
- a higher chance for getting infections. 1103

1104 Who should not receive Rituxan?

Do not use Rituxan if you ever had an allergic reaction to Rituxan. 1105

1106	What should I tell my doctor before treatment with Rituxan?
1107	Tell your doctor about all of your medical conditions, including if you:
1108 1109	• have an infection or have an infection that will not go away or that keeps coming back.
1110	• are scheduled to have surgery.
1111 1112 1113 1114	• have had hepatitis B virus infection or are a carrier of hepatitis B virus. Your doctor should check you closely for signs of a hepatitis infection during treatment with Rituxan and for several months after treatment ends.
1115 1116	• have any scheduled vaccinations. It is not known if Rituxan affects your ability to respond to vaccines.
1117	• have heart or lung problems.
1118 1119	• are pregnant or planning to become pregnant. It is not known if Rituxan can harm your unborn baby.
1120 1121	• are breastfeeding. It is not known if Rituxan passes into human breast milk. You should not breastfeed while being treated with Rituxan.
1122	Tell your doctor about all the other medicines you take, including
1123	prescription and nonprescription medicines, vitamins, or herbal
1124	supplements. If you have RA, tell your doctor if you are taking or took
1125	another biologic medicine called a TNF inhibitor or a DMARD (disease
1126	modifying anti-rheumatic drug).
1127	How do I receive Rituxan?
1128 1129 1130	• Rituxan is given through a needle placed in a vein (IV infusion), in your arm. Rituxan therapy is given in different ways for NHL and RA. Talk to your doctor about how you will receive Rituxan.
1131 1132 1133	• Your doctor may prescribe other medicines before each infusion of Rituxan to prevent or reduce pain, or to reduce fever and allergic reactions.
1134	• Your doctor should do regular blood tests to check for side effects or

1135 reactions to Rituxan.

1136 What are possible side effects with Rituxan? Rituxan can cause the following serious side effects, some of which could 1137 be life-threatening side effects, including (See "What is the most 1138 important safety information I should know about Rituxan?") 1139 1140 Infusion reactions 1141 Tumor Lysis Syndrome (TLS) • 1142 Severe skin reactions • Progressive Multifocal Leukoencephalopathy (PML) 1143 Other serious side effects with Rituxan include: 1144 Hepatitis B virus reactivation. Tell your doctor if you had 1145 Hepatitis B virus or are a carrier of Hepatitis B virus. Rituxan may 1146 make you sick with Hepatitis B virus again and cause serious liver 1147 problems. People with active liver disease due to Hepatitis B should 1148 1149 stop receiving Rituxan. 1150 Heart Problems. Tell your doctor about any heart problems you have including chest pain (angina) and irregular heart beats. Rituxan 1151 can cause chest pain and irregular heart beats which may require 1152 1153 treatment. 1154 Infections. Rituxan can increase your chances for getting infections. • Call your doctor right away if you have a persistent cough, fever, 1155 chills, congestion, or any flu-like symptoms while receiving Rituxan. 1156 1157 These symptoms may be signs of a serious infection. 1158 Stomach and bowel problems. Serious stomach and bowel 1159 problems have been seen when Rituxan has been used with anti-cancer medicines in some patients with non-Hodgkin's 1160 lymphoma. Call your doctor right away if you have any stomach area 1161 1162 pain during treatment with Rituxan. 1163 Common side effects with Rituxan include: Fever, chills, shakes, itching, hives, sneezing, swelling, throat irritation or 1164 1165 tightness, and cough. These usually occur within 24 hours after the first infusion. Other common side effects include headache, nausea, upper 1166

> U.S. BL 103705/5262 Amendment: Rituximab—Genentech, Inc. 47 of 48/Regional (CBE) (Infections and Kaposi's Sarcoma): clean-labeltext.doc

- 1167 respiratory tract infection, and aching joints. If you have any of these1168 symptoms, tell your doctor or nurse.
- 1169 What if I still have questions?
- 1170 If you have any questions about Rituxan or your health, talk with your
- 1171 doctor. You can also visit the Rituxan internet sites at www.Rituxan.com
- 1172 or the companies' internet sites at www.Gene.com or
- 1173 www.Biogenidec.com or call 1-877-4-Rituxan (877-474-8892).
- 1174 Jointly Marketed by: Biogen Idec Inc. and Genentech, Inc.
- 1175 Manufactured by:
- 1176 Genentech, Inc.
- 1177 1 DNA Way
- 1178 South San Francisco, CA 94080-4990
- [©]2007 Biogen Idec Inc. and Genentech, Inc.
- 1180 Patient Information Approval February 21, 2007